Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Nucleic Acid-based Therapeutics Market

ID: MRFR/Pharma/2192-HCR
200 Pages
Satyendra Maurya
Last Updated: May 15, 2026

Nucleic Acid-Based Therapeutics Market Research Report By Therapeutic Type (Antisense Oligonucleotides, RNA Interference, Gene Therapy, CRISPR, DNA Vaccines), By Application (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases), By Route of Administration (Injectable, Oral, Topical), By End User (Hospitals, Research Institutions, Pharmaceutical Companies, Biotechnology Companies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Nucleic Acid-based Therapeutics Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Application (USD Million) | |
      1. 4.1.1 Gene Therapy | |
      2. 4.1.2 Antisense Oligonucleotides | |
      3. 4.1.3 RNA Interference | |
      4. 4.1.4 CRISPR Technology | |
      5. 4.1.5 Vaccines |
    2. 4.2 Healthcare, BY Type (USD Million) | |
      1. 4.2.1 DNA-based Therapeutics | |
      2. 4.2.2 RNA-based Therapeutics | |
      3. 4.2.3 Oligonucleotide Therapeutics | |
      4. 4.2.4 Gene Editing Technologies |
    3. 4.3 Healthcare, BY Delivery Method (USD Million) | |
      1. 4.3.1 Viral Vectors | |
      2. 4.3.2 Lipid Nanoparticles | |
      3. 4.3.3 Electroporation | |
      4. 4.3.4 Microinjection | |
      5. 4.3.5 Naked Nucleic Acids |
    4. 4.4 Healthcare, BY Region (USD Million) | |
      1. 4.4.1 North America | | |
        1. 4.4.1.1 US | | |
        2. 4.4.1.2 Canada | |
      2. 4.4.2 Europe | | |
        1. 4.4.2.1 Germany | | |
        2. 4.4.2.2 UK | | |
        3. 4.4.2.3 France | | |
        4. 4.4.2.4 Russia | | |
        5. 4.4.2.5 Italy | | |
        6. 4.4.2.6 Spain | | |
        7. 4.4.2.7 Rest of Europe | |
      3. 4.4.3 APAC | | |
        1. 4.4.3.1 China | | |
        2. 4.4.3.2 India | | |
        3. 4.4.3.3 Japan | | |
        4. 4.4.3.4 South Korea | | |
        5. 4.4.3.5 Malaysia | | |
        6. 4.4.3.6 Thailand | | |
        7. 4.4.3.7 Indonesia | | |
        8. 4.4.3.8 Rest of APAC | |
      4. 4.4.4 South America | | |
        1. 4.4.4.1 Brazil | | |
        2. 4.4.4.2 Mexico | | |
        3. 4.4.4.3 Argentina | | |
        4. 4.4.4.4 Rest of South America | |
      5. 4.4.5 MEA | | |
        1. 4.4.5.1 GCC Countries | | |
        2. 4.4.5.2 South Africa | | |
        3. 4.4.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Moderna (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 BioNTech (DE) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Gilead Sciences (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Amgen (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Regeneron Pharmaceuticals (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Vertex Pharmaceuticals (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Sangamo Therapeutics (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Ionis Pharmaceuticals (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 CureVac (DE) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY APPLICATION |
    7. 6.4 US MARKET ANALYSIS BY TYPE |
    8. 6.5 US MARKET ANALYSIS BY DELIVERY METHOD |
    9. 6.6 CANADA MARKET ANALYSIS BY APPLICATION |
    10. 6.7 CANADA MARKET ANALYSIS BY TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY DELIVERY METHOD |
    12. 6.9 EUROPE MARKET ANALYSIS |
    13. 6.10 GERMANY MARKET ANALYSIS BY APPLICATION |
    14. 6.11 GERMANY MARKET ANALYSIS BY TYPE |
    15. 6.12 GERMANY MARKET ANALYSIS BY DELIVERY METHOD |
    16. 6.13 UK MARKET ANALYSIS BY APPLICATION |
    17. 6.14 UK MARKET ANALYSIS BY TYPE |
    18. 6.15 UK MARKET ANALYSIS BY DELIVERY METHOD |
    19. 6.16 FRANCE MARKET ANALYSIS BY APPLICATION |
    20. 6.17 FRANCE MARKET ANALYSIS BY TYPE |
    21. 6.18 FRANCE MARKET ANALYSIS BY DELIVERY METHOD |
    22. 6.19 RUSSIA MARKET ANALYSIS BY APPLICATION |
    23. 6.20 RUSSIA MARKET ANALYSIS BY TYPE |
    24. 6.21 RUSSIA MARKET ANALYSIS BY DELIVERY METHOD |
    25. 6.22 ITALY MARKET ANALYSIS BY APPLICATION |
    26. 6.23 ITALY MARKET ANALYSIS BY TYPE |
    27. 6.24 ITALY MARKET ANALYSIS BY DELIVERY METHOD |
    28. 6.25 SPAIN MARKET ANALYSIS BY APPLICATION |
    29. 6.26 SPAIN MARKET ANALYSIS BY TYPE |
    30. 6.27 SPAIN MARKET ANALYSIS BY DELIVERY METHOD |
    31. 6.28 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
    32. 6.29 REST OF EUROPE MARKET ANALYSIS BY TYPE |
    33. 6.30 REST OF EUROPE MARKET ANALYSIS BY DELIVERY METHOD |
    34. 6.31 APAC MARKET ANALYSIS |
    35. 6.32 CHINA MARKET ANALYSIS BY APPLICATION |
    36. 6.33 CHINA MARKET ANALYSIS BY TYPE |
    37. 6.34 CHINA MARKET ANALYSIS BY DELIVERY METHOD |
    38. 6.35 INDIA MARKET ANALYSIS BY APPLICATION |
    39. 6.36 INDIA MARKET ANALYSIS BY TYPE |
    40. 6.37 INDIA MARKET ANALYSIS BY DELIVERY METHOD |
    41. 6.38 JAPAN MARKET ANALYSIS BY APPLICATION |
    42. 6.39 JAPAN MARKET ANALYSIS BY TYPE |
    43. 6.40 JAPAN MARKET ANALYSIS BY DELIVERY METHOD |
    44. 6.41 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
    45. 6.42 SOUTH KOREA MARKET ANALYSIS BY TYPE |
    46. 6.43 SOUTH KOREA MARKET ANALYSIS BY DELIVERY METHOD |
    47. 6.44 MALAYSIA MARKET ANALYSIS BY APPLICATION |
    48. 6.45 MALAYSIA MARKET ANALYSIS BY TYPE |
    49. 6.46 MALAYSIA MARKET ANALYSIS BY DELIVERY METHOD |
    50. 6.47 THAILAND MARKET ANALYSIS BY APPLICATION |
    51. 6.48 THAILAND MARKET ANALYSIS BY TYPE |
    52. 6.49 THAILAND MARKET ANALYSIS BY DELIVERY METHOD |
    53. 6.50 INDONESIA MARKET ANALYSIS BY APPLICATION |
    54. 6.51 INDONESIA MARKET ANALYSIS BY TYPE |
    55. 6.52 INDONESIA MARKET ANALYSIS BY DELIVERY METHOD |
    56. 6.53 REST OF APAC MARKET ANALYSIS BY APPLICATION |
    57. 6.54 REST OF APAC MARKET ANALYSIS BY TYPE |
    58. 6.55 REST OF APAC MARKET ANALYSIS BY DELIVERY METHOD |
    59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
    60. 6.57 BRAZIL MARKET ANALYSIS BY APPLICATION |
    61. 6.58 BRAZIL MARKET ANALYSIS BY TYPE |
    62. 6.59 BRAZIL MARKET ANALYSIS BY DELIVERY METHOD |
    63. 6.60 MEXICO MARKET ANALYSIS BY APPLICATION |
    64. 6.61 MEXICO MARKET ANALYSIS BY TYPE |
    65. 6.62 MEXICO MARKET ANALYSIS BY DELIVERY METHOD |
    66. 6.63 ARGENTINA MARKET ANALYSIS BY APPLICATION |
    67. 6.64 ARGENTINA MARKET ANALYSIS BY TYPE |
    68. 6.65 ARGENTINA MARKET ANALYSIS BY DELIVERY METHOD |
    69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
    70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
    71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY DELIVERY METHOD |
    72. 6.69 MEA MARKET ANALYSIS |
    73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
    74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
    75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY DELIVERY METHOD |
    76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
    77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
    78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY DELIVERY METHOD |
    79. 6.76 REST OF MEA MARKET ANALYSIS BY APPLICATION |
    80. 6.77 REST OF MEA MARKET ANALYSIS BY TYPE |
    81. 6.78 REST OF MEA MARKET ANALYSIS BY DELIVERY METHOD |
    82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
    83. 6.80 RESEARCH PROCESS OF MRFR |
    84. 6.81 DRO ANALYSIS OF HEALTHCARE |
    85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
    88. 6.85 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
    89. 6.86 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million) |
    90. 6.87 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
    91. 6.88 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million) |
    92. 6.89 HEALTHCARE, BY DELIVERY METHOD, 2024 (% SHARE) |
    93. 6.90 HEALTHCARE, BY DELIVERY METHOD, 2024 TO 2035 (USD Million) |
    94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    95. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.2.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.2.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.3.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.3.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.4.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.4.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.5.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.5.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.6.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.6.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.7.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.7.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.8.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.8.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.9.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.9.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.10.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.10.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.11.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.11.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.12.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.12.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.13.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.13.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.14.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.14.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.15.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.15.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.16.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.16.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.17.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.17.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.18.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.18.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.19.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.19.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.20.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.20.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.21.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.21.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.22.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.22.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.23.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.23.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.24.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.24.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.25.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.25.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.26.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.26.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.27.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.27.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.28.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.28.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.29.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.29.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.30.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.30.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
    125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    126. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Application (USD Million, 2025-2035)

  • Gene Therapy
  • Antisense Oligonucleotides
  • RNA Interference
  • CRISPR Technology
  • Vaccines

Healthcare By Type (USD Million, 2025-2035)

  • DNA-based Therapeutics
  • RNA-based Therapeutics
  • Oligonucleotide Therapeutics
  • Gene Editing Technologies

Healthcare By Delivery Method (USD Million, 2025-2035)

  • Viral Vectors
  • Lipid Nanoparticles
  • Electroporation
  • Microinjection
  • Naked Nucleic Acids

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions